Association of transdermal fentanyl and oral transmucosal fentanyl citrate in the treatment of opioid naive patients with severe chronic noncancer pain

Journal of Opioid Management

Volumn 4, Issue 2, 2008, Pages 111-115

  Collado, Francisco ^a   Torres, Luis M ^b  

^a UNIVERSITY OF CÁDIZ   (Spain)

^b HOSPITAL UNIVERSITARIO PUERTA DEL MAR   (Spain)

Author keywords

Analgesics opioid; Chronic disease drug therapy; Fentanyl administration and dosage; Fentanyl adverse effects; Pain drug therapy

Indexed keywords

FENTANYL; FENTANYL CITRATE; LAXATIVE; OPIATE;

ADULT; AGED; ARTICLE; CHRONIC PAIN; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS; DISEASE DURATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PAIN ASSESSMENT; PROSPECTIVE STUDY; SINGLE DRUG DOSE; SLEEP; SOMNOLENCE; UNSPECIFIED SIDE EFFECT; VISUAL ANALOG SCALE;

EID: 45249110953     PISSN: 15517489     EISSN: None     Source Type: Journal    
DOI: 10.5055/jom.2008.0016     Document Type: Article

References (32)

1. Gureje O, Von Korff M, Simon GE, et al.: Persistent pain and well being. A World Health Organization Study in primary care. JAMA. 1998; 280: 147-151.
2. Reid MC, Engles-Horton LL, Weber MB, et al.: Use of opioid medications for chronic noncancer pain syndromes in primary care. J Gen Intern Med. 2002; 17: 173-179.
3. Clark JD: Chronic pain prevalence and analgesic prescribing in a general medical population. J Pain Symptom Manage. 2002; 23: 131-137.
4. Bannwarth B: Risk-benefit assessment of opioids in chronic noncancer pain. Drug Safety. 1999; 21: 283-296.
5. Jage J: Opioid tolerance and dependence-Do they matter? Eur J Pain. 2005; 9: 157-162.
6. Kahan M, Srivastava A, Wilson L, et al.: Misuse and dependence on opioids. Can Fam Physician. 2006; 52: 1081-1087.
7. Breivik H, Collett B, Ventafrida V, et al.: Survey of chronic pain in Europe: Prevalence, impact on daily life, and treatment. Eur J Pain. 2006; 10: 287-333.
8. World Health Organization: Cancer pain relief and palliative care. Report of a WHO Expert Committee. World Health Organization Technical Report Series(second edition). Geneva, Switzerland, WHO, 1996.
9. Torres LM, Calderón E, Pernia A, et al.: De la escalera al ascensor. Rev Soc Esp Dolor. 2002; 9: 289-290.
10. Mystakidou K, Tsilika E, Parpa E, et al.: Long-term cancer pain management in morphine pre-treated and opioid naive patients with transdermal fentanyl. Int J Cancer. 2003; 107: 486-492.
11. Furlan AD, Sandoval JA, Mailis-Gagnon A, et al.: Opioids for chronic noncancer pain: A meta-analysis of effectiveness and side effects. Canadian Med Assoc J. 2006; 174: 1589-1594.
12. Milligan K, Lanteri-Minet M, Borchert K, et al.: Evaluation of long-term efficacy and safety of transdermal fentanyl in the treatment of chronic noncancer pain. J Pain. 2001; 2: 197-204.
13. Kornick CA, Santiago-Palma J, Moryl N, et al.: Benefit-risk assessment of transdermal fentanyl for the treatment of chronic pain. Drug Safety. 2003; 26: 951-973.
14. Clark AJ, Ahmedzai SH, Allan LG, et al.: Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain. Curr Med Res Opin. 2004; 20: 1419-1428.
15. Allan L, Richarz U, Simpson K, et al.: Transdermal fentanyl versus sustained release oral morphine in strong-opioid naïve patients with chronic low back pain. Spine. 2005; 30: 2484-2490.
16. Otis J, Rothman M: A phase III study to assess the clinical utility of low-dose fentanyl transdermal system in patients with chronic non-malignant pain. Curr Med Res Opin. 2006; 22: 1493-1501.
17. Langford R, McKenna F, Ratcliffe S, et al.: Transdermal fentanyl for improvement of pain and functioning in osteoarthritis: A randomized, placebo-controlled trial. Arthritis Rheum. 2006; 54: 1829-1837.
18. Fine PG, Streisand JB: A review of oral transmucosal fentanyl citrate: Potent, rapid and non-invasive opioid analgesia. J Palliat Med. 1998; 1: 55-63.
19. Farrar JT, Cleary J, Rauck R, et al.: Oral transmucosal fentanyl citrate: Randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients. J Natl Cancer Inst. 1998; 90: 611-616.
20. Coluzzi PH, Schwatzberg L, Conroy JD Jr, et al.: Breakthrough cancer pain: A randomized trial comparing oral transmucosal fentanyl citrate (OTFC®) and morphine sulfate immediate release (MSIR®). Pain. 2001; 91: 123-130.
21. Freynhagen RM, Jürgen von Giesen H, Busche P, et al.: Switching from reservoir to matrix systems for the transdermal delivery of fentanyl: A prospective, multicenter pilot study in outpatients with chronic pain. J Pain Symptom Manage. 2005; 30: 289-297.
22. Christie JM, Simmonds M, Patt R, et al.: Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain. J Clin Oncol. 1998; 16: 3238-3245.
23. Trelis J, Pérez-Hernández C, Sánchez-Domínguez F, et al.: Transmucosal oral fentanyl citrate for the management of irruptive pain suffered by cancer patients in Spain: Results of the EDIPAD study. [Article in Spanish]. Rev Soc Esp Dolor. 2004; 11: 184-196.
24. Cepeda MS, Farrar JT, Baumgarten M, et al.: Side effects of opioids during short-term administration: Effect of age, gender, and race. Clin Pharmacol Ther. 2003; 74: 102-112.
25. Wilder-Smith OHG: Opioid use in the elderly. Eur J Pain. 2005; 9: 137-140.
26. Donner B, Zenz M, Tryba M, et al.: Direct conversion from oral morphine to transdermal fentanyl: A multicenter study in patients with cancer pain. Pain. 1996; 64: 527-534.
27. Ackerman SJ, Knight T, Schein J, et al.: Risk of constipation in patients prescribed fentanyl transdermal system or oxycodone hydrochloride controlled-release in a California Medicaid population. Consult Pharm. 2004; 19: 118-132.
28. Ahmedzai S, Brooks D, on behalf of the TTS-Fentanyl Comparative Trial Group: Transdermal fentanyl versus sustained-release oral morphine in cancer pain: Preference, efficacy, and quality of life. J Pain Symptom Manage. 1997; 13: 254-261.
29. Sabatowski R, Schwalen S, Rettig K, et al.: Driving ability under long-term treatment with transdermal fentanyl. J Pain Symptom Manage. 2003; 25: 38-47.
30. Menefee LA, Frank ED, Crerand C, et al.: The effects f transdermal fentanyl on driving, cognitive performance, and balance in patients with chronic nonmalignant pain conditions. Pain Med. 2004; 5: 42-49.
31. Zeppetella G, Ribeiro MD: Opioids for the management of breakthrough (episodic) pain in cancer patients. Cochrane Database Syst Rev. 2006; 1: CD004311.
32. Mystakidou K, Katsoude E, Parpa E, et al.: Oral transmucosal fentanyl citrate: Overview of pharmacological and clinical characteristic. Drug Deliv. 2006; 13: 269-276.